Abstract: The invention relates to a quantum cascade laser (300) comprising a gain region (102) inserted between two optical confinement layers (1041, 1042), said gain region (102) having an electron input into the gain region (102) and an electron output from said gain region (102) characterized in that said laser comprises a hole-blocking area (304) on the side of said electron output.

Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.

Abstract: The present invention relates to a method for classifying a measurement biological sample, comprising: acquisition of at least one DNA melting curve of the measurement biological sample, called at least one measurement curve; and determination that the measurement biological sample belongs to a defined group among different possible groups, by analysis of descriptors originating from the at least one measurement curve, characterized in that the descriptors comprise one or more points of the first derivative of each measurement curve and/or comprise one or more points of the second derivative of each measurement curve and/or one or more points of each measurement curve and/or one or more percentiles of each measurement curve. The invention also relates to a device implementing this method.

Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.

Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a follicular fluid sample.

Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.

Abstract: The present disclosure generally relates to methods and devices for determining the attitude of a spacecraft by capturing a photograph of a starry sky, determining at least one potential star from the photograph, extracting for at least one potential star a spot pattern based upon rings having a similar area, searching a database for selecting a list of best candidate stars, verifying if the spot may be positively identified as a reference star by matching the spot with best candidate reference stars from a database, positively identifying at least one potential star, and determining the attitude of the spacecraft based upon at least one positively identified star.

Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will no

Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

Abstract: Disclosed is a method for reducing organic compounds using catalysts containing nickel (0) from metal hyperaccumulator plants. The method can be implemented in a green manner and is advantageous compared to methods using the known catalysts.

Abstract: The present disclosure relates to the use of a biopolymer as a sensitive material in a dielectric gas sensor for water vapor, carbon dioxide, and/or ethanol.

Abstract: A proton-conductive electrochemical device. The device comprising a positive electrode able to reduce an oxidizing species, a negative electrode able to oxidize a reducing species, and a proton-conductive electrolyte, in contact with the positive electrode and the negative electrode. In addition, the device further comprises a layer able to diffuse protons and electrons, said layer forming a protective barrier against contaminants for the proton-conductive electrolyte. The layer is in contact with the proton-conductive electrolyte on the one hand and the negative electrode on the other hand. A method for manufacturing such device is also provided.

Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.

Abstract: A laser device for generating an optical wave including at least two frequencies, such laser device including: a first element including a gain region, a second mirror, distinct from the first element, and arranged so as to form with a first mirror an optical cavity including the gain region; means for pumping the gain region so as to generate the optical wave; means for shaping the light intensity of the optical wave arranged for selecting at least two transverse modes of the optical wave; and means for shaping the longitudinal and/or transversal phase profile of the optical wave and arranged for adjusting at least two transverse modes of the optical wave.

Abstract: A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to an organic-inorganic hybrid material which comprises an inorganic solid support on which are grafted organic molecules of the general formula (I) hereafter: and relates to methods allowing preparation of this hybrid material as well as to the uses of the hybrid material for extracting uranium(VI) from an aqueous medium comprising phosphoric acid.

Abstract: A molecule responding to formula (I) of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa, more specifically as inhibitors of Pseudomonas aeruginosa's virulence.